AbbVie raises annual targets
It reports adjusted EPS of $2.31 for the first quarter 2024, down 6.1% year-on-year, despite sales of over $12.3 billion, up 0.7% on a reported basis.
On an operational basis - i.e., excluding currency effects - revenues rose by 1.6%, with growth in oncology (+9.8%) and neuroscience (+16%) more than offsetting declines in its other portfolios.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction